Dr. Yang joined Bain Capital Life Sciences in 2019. She is an Associate.
Prior to joining Bain Capital, Dr. Yang was a Fellow at Qiming Venture Partners USA, assessing novel technologies. Prior to her VC fellowship, Dr. Yang was a consultant analyst at a life science consultancy firm, where she performed valuation, landscaping, and market research for biopharma and investment companies. Prior to her consultant role, Dr. Yang was a scientist at the pioneering RNAi company Dicerna Pharmaceuticals, where she was actively involved in establishing the company’s RNAi technology platform, and spearheaded lead identification for cardiovascular disease programs. Prior to Dicerna, Dr. Yang was a postdoctoral fellow in the Department of Microbiology and Immunobiology at Harvard Medical School, where she conducted research on hepatitis C virus. During her PhD studies at Cornell, Dr. Yang focused on miRNA biology and technology platform development.
Dr. Yang received her PhD in Biochemistry and Molecular Biology from Weill Cornell Graduate School of Medical Sciences. She also received an MBA from INSEAD, France. She graduated from National Taiwan University with a BSc in Biochemical Science & Technology.